ArticleFrontiers in oncology2025
IL-36-related genes predict prognosis of gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in spasmolytic polypeptide expressing metaplasia research.World journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer (GC) is one of the most frequently encountered malignant tumors in the clinic. Because effective early screening techniques are lacking, most patients have advanced disease at first diagnosis. The interleukin (IL)-36 family plays a vital role in regulating the immune system, inflammatory responses, and the occurrence and development of cancer. Hence, this study explored the potential role of IL-36 related genes (IL-36RGs) in GC and built a prognostic risk assessment model for GC based on IL-36RGs, which can help evaluate treatment and prognosis. Methods: First, relevant datasets were downloaded from public databases. After processing the datasets to remove batch effects, perform differential analysis, and take intersections, IL-36-related differentially expressed genes (IL-36RDEGs) were screened. A prognostic risk model containing nine model genes was constructed based on univariate Cox and least absolute shrinkage and selection operator (LASSO) regression methods. Then, to investigate the potential biological activities of the model genes in GC, we conducted enrichment, PPI interaction network, and immune infiltration analyses. Immunohistochemical staining was conducted to validate the expression of IL-36A in GC. Results: The prognostic risk model analysis revealed that mortality events in the high-risk group were substantially elevated compared to those in the low-risk group. The model demonstrated excellent predictive capability at 1, 2, and 3 years and showed the best clinical predictive performance at 3 years. Bioinformatics analysis of the model genes indicate that they primarily participate in mechanisms that promote the synthesis and secretion of cytokines in GC. And hub genes may be strongly correlated with host immune response mechanisms. According to the immunohistochemical staining results, IL-36A expression was higher in the STAD group than in the control group. Conclusions: The results of the above analysis suggest that IL-36RDEGs can serve as independent prognostic biomarkers for GC and provide insights into IL-36RGs from both bioinformatics and experimental validation perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.